GH1 and growth hormone-producing pituitary gland neoplasm: Pasireotide has shown to be more effective in lowering GH levels than octreotide in tumors with relatively high SSTR5 expression [38], and a higher SSTR5 expression has been found in somatotropinomas to be poorly responsive to octreotide [39].